article thumbnail

Scientists home in on cause of Duchenne gene therapy side effect

Bio Pharma Dive

An unusual collaboration among gene therapy developers suggests certain mutations could be behind "peculiar" side effects experienced by several patients treated in clinical trials.

article thumbnail

Scientists Just Identified Hundreds of Genes That Could Cause Cancer

AuroBlog - Aurous Healthcare Clinical Trials blog

(Richard Jones/Science Photo Library/Getty Images) Scientists have discovered hundreds of genes that could potentially promote cancer, new research shows. Cancer is typically triggered by some kind of change to our genetic coding that interferes with a cell’s ability to manage its growth.

Scientist 244
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Intellia, expanding in gene editing, buys startup Rewrite for $45M

Bio Pharma Dive

Founded by University of California, Berkeley scientists, Rewrite is studying ways to expand the reach of gene editing beyond limitations of current technologies, including Intellia's.

article thumbnail

This Rare Gene Variant Seems to Protect You From Alzheimer’s Disease

AuroBlog - Aurous Healthcare Clinical Trials blog

A woman in Colombia with rare genetic resistance to Alzheimer’s disease may have more company than scientists thought.

Gene 245
article thumbnail

A new startup from Feng Zhang and an ex-Illumina executive zeroes in on the epigenome

Bio Pharma Dive

Moonwalk Biosciences, the latest biotech cofounded by the gene editing scientist, joins other startups aiming to alter gene expression without changing DNA.

article thumbnail

Gladstone and UCSF scientists discover BET protein role in Covid-19

Pharmaceutical Technology

Furthermore, researchers found that one of the genes turned on by these BET proteins is ACE2, the same protein that the virus depends on to get into cells. In the latest study, Gladstone graduate student Irene Chen and the team found that the BET proteins switch on genes that block viruses, in SARS-CoV-2 infected cells.

Protein 278
article thumbnail

FDA grants approval for CSL’s haemophilia B gene therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for CSL Behring’s adeno-associated virus vector-based gene therapy, Hemgenix (etranacogene dezaparvovec), to treat haemophilia B (congenital Factor IX deficiency) in adult patients. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.